Horizon Pharma (HZNP) Rating Increased to Hold at Zacks Investment Research - Fairfield Current

Horizon Pharma (HZNP) Rating Increased to Hold at Zacks Investment Research  Fairfield Current

Horizon Pharma (NASDAQ:HZNP) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued on Friday.



Comments

Popular posts from this blog

Urinary Tract Infection (UTI): Causes, Symptoms & Treatment - Cleveland Clinic

Rashes that look like scabies: Causes, symptoms, and treatment - Medical News Today